Predictive Oncology (NASDAQ:POAI) Stock Passes Below 200 Day Moving Average of $2.93

Predictive Oncology Inc. (NASDAQ:POAI) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.93 and traded as low as $1.29. Predictive Oncology shares last traded at $1.34, with a volume of 24,355 shares traded.

Predictive Oncology Trading Up 3.9 %

The firm has a market capitalization of $5.44 million, a P/E ratio of -0.39 and a beta of 1.28. The company’s fifty day simple moving average is $2.52 and its 200 day simple moving average is $2.93.

Predictive Oncology (NASDAQ:POAI) last issued its quarterly earnings data on Thursday, March 28th. The medical instruments supplier reported ($0.85) EPS for the quarter. Predictive Oncology had a negative return on equity of 104.21% and a negative net margin of 785.62%. The company had revenue of $0.34 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Predictive Oncology stock. Carnegie Mellon University purchased a new position in Predictive Oncology Inc. (NASDAQ:POAI) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 10,358 shares of the medical instruments supplier’s stock, valued at approximately $34,000. Predictive Oncology makes up 0.0% of Carnegie Mellon University’s portfolio, making the stock its 5th biggest holding. Carnegie Mellon University owned about 0.26% of Predictive Oncology as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 9.04% of the company’s stock.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.